Xencor (XNCR) Competitors $25.04 +0.52 (+2.12%) (As of 12/17/2024 05:46 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends XNCR vs. LNTH, NUVL, LEGN, BPMC, ELAN, CYTK, TGTX, VKTX, BBIO, and CRNXShould you be buying Xencor stock or one of its competitors? The main competitors of Xencor include Lantheus (LNTH), Nuvalent (NUVL), Legend Biotech (LEGN), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), Cytokinetics (CYTK), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), BridgeBio Pharma (BBIO), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry. Xencor vs. Lantheus Nuvalent Legend Biotech Blueprint Medicines Elanco Animal Health Cytokinetics TG Therapeutics Viking Therapeutics BridgeBio Pharma Crinetics Pharmaceuticals Xencor (NASDAQ:XNCR) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends, valuation and community ranking. Does the media refer more to XNCR or LNTH? In the previous week, Xencor had 4 more articles in the media than Lantheus. MarketBeat recorded 8 mentions for Xencor and 4 mentions for Lantheus. Lantheus' average media sentiment score of 1.65 beat Xencor's score of 0.78 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 2 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is XNCR or LNTH more profitable? Lantheus has a net margin of 28.57% compared to Xencor's net margin of -232.77%. Lantheus' return on equity of 44.29% beat Xencor's return on equity.Company Net Margins Return on Equity Return on Assets Xencor-232.77% -30.92% -21.74% Lantheus 28.57%44.29%23.52% Which has more volatility and risk, XNCR or LNTH? Xencor has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Do institutionals and insiders hold more shares of XNCR or LNTH? 99.1% of Lantheus shares are owned by institutional investors. 5.2% of Xencor shares are owned by company insiders. Comparatively, 1.5% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has stronger valuation & earnings, XNCR or LNTH? Lantheus has higher revenue and earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXencor$85.16M20.58-$126.09M-$3.20-7.83Lantheus$1.50B4.30$326.66M$6.0115.42 Does the MarketBeat Community prefer XNCR or LNTH? Xencor received 168 more outperform votes than Lantheus when rated by MarketBeat users. Likewise, 73.44% of users gave Xencor an outperform vote while only 65.76% of users gave Lantheus an outperform vote. CompanyUnderperformOutperformXencorOutperform Votes50673.44% Underperform Votes18326.56% LantheusOutperform Votes33865.76% Underperform Votes17634.24% Do analysts rate XNCR or LNTH? Xencor presently has a consensus target price of $36.56, indicating a potential upside of 45.99%. Lantheus has a consensus target price of $130.00, indicating a potential upside of 40.30%. Given Xencor's stronger consensus rating and higher possible upside, equities analysts clearly believe Xencor is more favorable than Lantheus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xencor 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Lantheus 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 SummaryXencor beats Lantheus on 10 of the 19 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Xencor News Delivered to You Automatically Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XNCR vs. The Competition Export to ExcelMetricXencorPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.75B$6.87B$5.18B$9.32BDividend YieldN/A3.06%4.78%4.06%P/E Ratio-7.8310.75128.0017.55Price / Sales20.58288.101,260.27139.72Price / CashN/A56.6541.1637.95Price / Book2.285.394.874.92Net Income-$126.09M$152.04M$119.61M$225.78M7 Day Performance-0.99%-5.54%14.55%-1.48%1 Month Performance8.54%0.33%17.42%5.36%1 Year Performance19.69%16.04%35.34%22.71% Xencor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XNCRXencor4.1787 of 5 stars$25.04+2.1%$36.56+46.0%+19.7%$1.75B$85.16M-7.83280LNTHLantheus4.4014 of 5 stars$94.83+1.9%$130.00+37.1%+21.9%$6.59B$1.50B15.42834Positive NewsNUVLNuvalent2.3399 of 5 stars$86.56-0.3%$112.60+30.1%+9.7%$6.15BN/A-25.0340Positive NewsLEGNLegend Biotech1.6722 of 5 stars$33.25-5.3%$81.54+145.2%-43.4%$6.07B$520.18M-36.971,800BPMCBlueprint Medicines2.9172 of 5 stars$95.33+2.3%$122.11+28.1%+9.7%$6.06B$434.42M-45.28640Insider TradeShort Interest ↑ELANElanco Animal Health4.2802 of 5 stars$12.18+0.7%$16.75+37.5%-10.5%$6.02B$4.45B30.259,300CYTKCytokinetics3.9849 of 5 stars$49.10+0.9%$83.93+70.9%+32.5%$5.79B$3.22M-9.04250TGTXTG Therapeutics3.8084 of 5 stars$34.56+7.9%$40.67+17.7%+81.7%$5.38B$233.66M-320.17290Positive NewsVKTXViking Therapeutics4.2772 of 5 stars$47.94+1.9%$106.75+122.7%+147.1%$5.34BN/A-51.5620BBIOBridgeBio Pharma4.7325 of 5 stars$27.75+0.9%$47.69+71.9%-29.3%$5.24B$217.77M-11.63400Analyst ForecastCRNXCrinetics Pharmaceuticals4.2142 of 5 stars$54.32+1.2%$70.82+30.4%+60.7%$5.04B$1.04M-14.39210Analyst ForecastShort Interest ↓Positive News Related Companies and Tools Related Companies Lantheus Alternatives Nuvalent Alternatives Legend Biotech Alternatives Blueprint Medicines Alternatives Elanco Animal Health Alternatives Cytokinetics Alternatives TG Therapeutics Alternatives Viking Therapeutics Alternatives BridgeBio Pharma Alternatives Crinetics Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XNCR) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xencor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XNCR Stock Alerts